financetom
Business
financetom
/
Business
/
Why Ascent Solar Stock Is Climbing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Ascent Solar Stock Is Climbing
Jun 21, 2024 8:24 AM

Ascent Solar Technologies, Inc. ( ASTI ) shares are trading higher Friday after the company announced it has paid off outstanding balances on a securities purchase contract. 

The Details:

The company provided a corporate update on the securities purchase contract with an institutional investor previously disclosed on Dec. 19, 2022, pursuant to which the company issued $12.5 million in convertible advance notes and an additional $2.5 million in convertible advance notes in a concurrent private placement transaction.

Ascent Solar ( ASTI ) said it has paid the remaining institutional investor’s notes payable and related liabilities and no further obligations exist under the securities purchase contract.

Ascent Solar ( ASTI ) shares are moving on heavy trading volume following the announcement. According to data from Benzinga Pro, more than 72 million shares have been traded before the opening bell in Friday's session.

Related News: Why EV Maker Nikola’s Stock Is Crashing

How To Buy ASTI Stock:

By now you're likely curious about how to participate in the market for Ascent Solar Technologies ( ASTI ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

ASTI Price Action: According to Benzinga Pro, Ascent Solar Technologies ( ASTI ) shares are up 8.5% at 11 cents at the time of publication Friday.

Image: Leopictures from Pixabay

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Portillo's Insider Sold Shares Worth $679,675, According to a Recent SEC Filing
Portillo's Insider Sold Shares Worth $679,675, According to a Recent SEC Filing
Aug 12, 2024
03:56 PM EDT, 08/12/2024 (MT Newswires) -- Michael Osanloo, Director, President & CEO, on August 09, 2024, sold 66,052 shares in Portillo's (PTLO) for $679,675. Following the Form 4 filing with the SEC, Osanloo has control over a total of 79,041 shares of the company, with 79,041 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1871509/000187150924000105/xslF345X03/wk-form4_1723492418.xml Price: 10.82, Change: +0.11, Percent Change: +1.03...
Update: Eli Lilly Looking to Issue Debt for Morphic Acquisition
Update: Eli Lilly Looking to Issue Debt for Morphic Acquisition
Aug 12, 2024
03:45 PM EDT, 08/12/2024 (MT Newswires) -- (Updates to reflect Eli Lilly ( LLY ) declined comment to MT Newswires) Eli Lilly ( LLY ) filed a prospectus Monday to raise debt for its $3.2 billion acquisition of Morphic. According to a securities filing, the pharma company is looking to issue five separate series of notes to raise $5 billion...
Novartis loses initial bid to block generic of best-selling heart drug
Novartis loses initial bid to block generic of best-selling heart drug
Aug 12, 2024
Aug 12 (Reuters) - Novartis failed to convince a Delaware federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court decision issued on Monday. U.S. District Judge Richard Andrews ruled that Novartis' chance of winning its patent-infringement lawsuit challenging the generic was too low to justify halting...
Esperion Therapeutics Shares Fall After Reporting Wider Than Expected Q2 Loss
Esperion Therapeutics Shares Fall After Reporting Wider Than Expected Q2 Loss
Aug 12, 2024
03:45 PM EDT, 08/12/2024 (MT Newswires) -- Esperion Therapeutics ( ESPR ) shares were down nearly 8% in recent Monday trading after the company reported a wider-than-expected Q2 net loss. The company reported a Q2 net loss of $0.33 per diluted share, compared with a loss of $0.46 a year earlier. Analysts polled by Capital IQ expected a $0.18 loss....
Copyright 2023-2026 - www.financetom.com All Rights Reserved